Put Collection Abstract here.

I-SPY 2 (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2) is an ongoing, multi-center trial designed to quickly identify new agents for breast cancer. Patients with high-risk disease are adaptively-randomized to either standard neoadjuvant chemotherapy (NAC) or one of several concurrent experimental arms. I-SPY 2 utilizes change in tumor volume by DCE-MRI at serial time-points during chemotherapy to adjust the randomization schema as the trial proceeds, preferentially assigning patients to receive agents showing an increasing likelihood of efficacy against their breast cancer subtype. I-SPY 2 opened in March 2010 at 20 clinical sites and is ongoing.

This collection includes DCE MRI data (original acquired and derived), and outcomes for 990 patients adaptively randomized to one of several different investigational regimens or control therapy between March 2010 and November 2016 with histopathologic outcome data.  Breast MRI data in this collection was acquired prospectively at over 20 clinical centers using a standardized image acquisition protocol. Patients underwent 4 MRI exams over treatment and over 95% of imaging data met acceptance criteria for analysis of functional tumor volume (FTV), a demonstrated quantitative imaging marker of breast cancer response to NAC. This is a comprehensive, highly curated imaging data set with histopathologic outcome that can be used to develop, test and compare imaging metrics and prediction models for breast cancer response to treatment.